47 related articles for article (PubMed ID: 31328453)
1. Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins's Lymphoma Patients-A Single Centre Experience.
Galunic Bilic L; Santek F; Mitrovic Z; Basic-Kinda S; Dujmovic D; Vodanovic M; Mandac Smoljanovic I; Ostojic Kolonic S; Galunic Cicak R; Aurer I
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339400
[TBL] [Abstract][Full Text] [Related]
2. Involved-field radiotherapy in older patients with superficial thoracic esophageal squamous cell carcinoma: long-term outcomes and recurrence patterns.
Kono S; Hashimoto Y; Ohmatsu K; Tsujii M; Kuribayashi S; Karasawa K
Jpn J Radiol; 2024 Apr; ():. PubMed ID: 38647885
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiation therapy for localized recurrent ovarian cancer.
Smart A; Chen YH; Cheng T; King M; Lee L
Int J Gynecol Cancer; 2019 May; ():. PubMed ID: 31053659
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
Kim YB; Byun HK; Wee CW; Kim H; Kim S; Yang G; Kim J; Park SJ; Lee JY
BMC Cancer; 2023 Oct; 23(1):1014. PubMed ID: 37864152
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment.
Shen J; Tao Y; He L; Guan H; Zhen H; Liu Z; Zhang F
Discov Oncol; 2022 Aug; 13(1):82. PubMed ID: 36006491
[TBL] [Abstract][Full Text] [Related]
6. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells.
Löblein MT; Falke I; Eich HT; Greve B; Götte M; Troschel FM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768932
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer.
Johns EA; Stanley JA; Toboni MD; Schwarz JK; Zhang F; Hagemann AR; Fuh KC; Thaker PH; McCourt CK; Mutch DG; Powell MA; Khabele D; Kuroki LM
Gynecol Oncol Rep; 2021 Aug; 37():100808. PubMed ID: 34169134
[TBL] [Abstract][Full Text] [Related]
8. Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis.
Yu L; Gong H; Li Q; Ren H; Wang Y; He H; Li T; Song Q
J Oncol; 2021; 2021():8849039. PubMed ID: 33628244
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
11. Involved-field radiation therapy for selected cases of recurrent ovarian cancer.
Kim N; Chang JS; Kim SW; Kim GM; Lee JY; Kim YB
J Gynecol Oncol; 2019 Sep; 30(5):e67. PubMed ID: 31328453
[TBL] [Abstract][Full Text] [Related]
12. Involved-field radiation therapy for locoregionally recurrent ovarian cancer.
Brown AP; Jhingran A; Klopp AH; Schmeler KM; Ramirez PT; Eifel PJ
Gynecol Oncol; 2013 Aug; 130(2):300-5. PubMed ID: 23648467
[TBL] [Abstract][Full Text] [Related]
13. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
Chang JS; Kim SW; Kim YJ; Kim JY; Park SY; Kim JH; Jang TK; Kim YB
Gynecol Oncol; 2018 Oct; 151(1):39-45. PubMed ID: 30146110
[TBL] [Abstract][Full Text] [Related]
14. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer.
Albuquerque KV; Singla R; Potkul RK; Smith DM; Creech S; Lo S; Emami B
Gynecol Oncol; 2005 Mar; 96(3):701-4. PubMed ID: 15721414
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
